Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if Premarin is useful against androgen-independent
prostate cancer and to help understand how drugs such as Premarin may work.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Emerson Hospital, Concord, MA Lowell General Hospital Massachusetts General Hospital Saint Anne's Hospital South Shore Hospital